Actively Recruiting
Evaluating Daily Rimegepant vs Placebo for Preventing Chronic Migraine in Adults
Led by Pfizer · Updated on 2026-10-14
400
Participants Needed
21
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of rimegepant, a medication that blocks calcitonin gene-related peptide CGRP receptors, for the preventive treatment of chronic migraine in adults. The study focuses on whether taking rimegepant once daily can reduce the number of migraine days compared to a placebo. This Phase 3 study involves approximately 400 adults aged 18 years or older who have had chronic migraine for at least one year. Participants first complete a 28-day observation period without any study treatment. Then, they are randomly assigned to receive either rimegepant 75 mg orally disintegrating tablets or a matching placebo once daily for 12 weeks in a double-blind phase. Those who finish this phase and remain eligible enter a 12-week open-label extension where all receive rimegepant 75 mg daily. During this extension, participants may take up to 10 additional doses of rimegepant monthly to treat breakthrough migraine attacks. The study concludes with a 28-day follow-up period. Throughout the trial, participants record migraine and headache details using an electronic diary and undergo regular assessments including laboratory tests, vital signs, and electrocardiograms. Researchers measure changes in monthly migraine days and other outcomes such as headache severity, medication use, quality of life, work productivity, and cognitive function. Safety and tolerability of daily rimegepant use are closely monitored, and the total study duration is about 32 weeks.
CONDITIONS
Brief Title
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here